Dexamethasone
Small molecule targets HDAC2 via activation
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | DEXTENZA | — | 2019-06-20 – 2025-04-07 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | OZURDEX | — | 2010-09-24 – 2014-06-28 | fda.gov ↗ |
| Approved | EU (EMA) | Ozurdex | — | 2010-07-26 | europa.eu ↗ |
| Approved | US (FDA) | DECADRON | — | 1958-10-30 | fda.gov ↗ |
Trials 1,755 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 031 trials · 2 met primary · 1 missed | ||||||
| Phase 0 | NCT07662200 | Aug 2026 → Aug 2027 expected | malignant germ cell tumor | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07343817 | Jul 2026 → Apr 2028 expected | — | Ahmed Nassar Ibrahim Mohammed | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07812259 | May 2026 → Jun 2027 expected | parotid gland neoplasm | Nîmes University Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07109258 | May → Sep 2025 overdue | — | Cairo University | Recruiting | No outcome recorded |
| Phase 0 | NCT06428630 | May 2025 → Sep 2026 | lichen planus, oral | Tufts University | Withdrawn | No outcome recorded |
| Phase 0 | NCT06894069 | Mar → May 2025 overdue | — | University of Jordan | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06432712 | Jan 2025 | — | Shoaib Rahim | Unknown | No outcome recorded |
| Phase 0 | NCT06142396 | Nov 2024 → Nov 2027 expected | kidney failure, plasma cell myeloma | Augusta University | Recruiting | No outcome recorded |
| Phase 0 | NCT06556095 | Sep 2024 → Jan 2026 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT05994183 | Oct 2023 → Mar 2025 | bronchiolitis | IDeA States Pediatric Clinical Trials Network | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT06016465 | Sep 2023 → Dec 2027 expected | migraine disorder | Texas Tech University Health Sciences Center, El Paso | Recruiting | No outcome recorded |
| Phase 0 | NCT05560399 | Feb 2023 → Nov 2026 expected | plasma cell myeloma | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05620901 | Feb 2023 → Feb 2025 | Coats disease, exudative vitreoretinopathy, retinal lattice degeneration, retinal perforation +1 | Lejla Vajzovic, MD, FASRS | Completed | Missed primary |
| Phase 0 | NCT04984330 | Dec 2021 → Jun 2023 | AL amyloidosis | Weill Medical College of Cornell University | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT04546126 | Nov 2021 → Dec 2026 expected | hypertensive disorder | Benjamin Viglianti | Recruiting | No outcome recorded |
| Phase 0 | NCT04895592 | Jul 2021 → Sep 2023 | metastatic malignant neoplasm in the brain | Emory University | Completed | Met primary |
| Phase 0 | NCT04889547 | Jul 2021 → Jul 2023 | — | Northwell Health | Completed | No outcome recorded |
| Phase 0 | NCT04945824 | Jun 2021 → Nov 2022 | — | Ocular Therapeutix, Inc. | Terminated | No outcome recorded |
| Phase 0 | NCT04418999 | Sep 2020 → Dec 2021 | dry eye syndrome, eye allergy, keratoconus | Illinois College of Optometry | Completed | No outcome recorded |
| Phase 0 | NCT04514029 | Aug 2020 → Nov 2023 overdue | lymphoma | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04019834 | Jul 2020 → Nov 2021 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT04037605 | Feb 2020 → Jul 2022 overdue | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03719105 | Mar 2019 → Dec 2027 expected | aggressive NK-cell leukemia | New York Medical College | Recruiting | No outcome recorded |
| Phase 0 | NCT03512223 | Oct 2018 → Oct 2024 | — | Ohio State University | Completed | Met primary |
| Phase 0 | NCT03122756 | Aug 2017 → Oct 2018 | — | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT02921893 | Oct 2016 → Apr 2022 | POEMS syndrome, plasmacytoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT02318433 | Dec 2014 → Jul 2019 | osteoarthritis | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT02109861 | Jan 2014 → Dec 2015 | plasma cell myeloma | Henrik Gregersen | Unknown | No outcome recorded |
| Phase 0 | NCT01878708 | Jul 2013 → Feb 2017 | T-cell non-Hodgkin lymphoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT02142543 | Mar → Dec 2012 | aphthous stomatitis | Texas A&M University | Completed | No outcome recorded |
| Phase 0 | NCT00314743 | Oct 2005 → Dec 2008 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1118 trials · 3 met primary · 1 missed | ||||||
| Phase 1 | NCT07341867 | Aug 2026 → Mar 2028 expected | plasma cell myeloma, triple-negative breast carcinoma | Andrew Hantel, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07513129 | Jun 2026 → Dec 2029 expected | T-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07426042 | Apr → May 2026 overdue | — | Min Kyu Park | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07224334 | Dec 2025 → Dec 2027 expected | diabetes mellitus | David D'Alessio, M.D. | Recruiting | No outcome recorded |
| Phase 1 | NCT07014462 | Sep 2025 → Jun 2029 expected | acute myeloid leukemia | University of Vermont | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07182110 | Aug 2025 → Aug 2026 overdue | gallbladder disorder | Makassed General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06348108 | Jul 2025 → Jul 2027 expected | plasma cell myeloma | Alfred Chung, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06863259 | May 2025 → Jan 2028 expected | B-cell acute lymphoblastic leukemia | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
| Phase 1 | NCT05773664 | Nov 2024 | glioblastoma | City of Hope Medical Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06433947 | Aug 2024 → Jul 2026 overdue | plasma cell myeloma | Opna Bio LLC | Recruiting | No outcome recorded |
| Show all 118 trials opens the full record — a long page | ||||||
| Phase 1/2102 trials · 7 met primary · 1 missed | ||||||
| Phase 1/2 | NCT07832110 | Oct 2026 → Dec 2028 expected | periodontitis | The University of Texas Health Science Center at San Antonio | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07601100 | Sep 2026 → Jul 2029 expected | plasma cell myeloma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06574048 | Jul 2026 → Jul 2027 expected | carbon monoxide-induced parkinsonism | University of Nebraska | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06930690 | Jun → Dec 2026 expected | — | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07479979 | May 2026 → Jul 2027 expected | plasma cell myeloma | Natalie Callander | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07504822 | Apr 2026 → Mar 2027 expected | acne | Yohanes Firmansyah, dr, MH, MM | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07388069 | Dec 2025 → Dec 2026 expected | keratoconus | TheiaNova Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06892522 | Jun 2025 → Feb 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06235567 | Apr 2025 → Dec 2026 expected | keratoconus | Maanasa Indaram, MD | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07024043 | Mar → Sep 2025 overdue | — | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06176027 | Oct 2024 → Sep 2028 expected | peripheral T-cell lymphoma, not otherwise specified | Navy General Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06559553 | Sep 2024 → Dec 2026 expected | T-cell and NK-cell neoplasm | Mingzhi Zhang | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05486481 | Jan 2024 → Dec 2028 | AL amyloidosis | Alfred Chung, MD | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06246162 | Nov 2023 → Nov 2025 overdue | plasma cell myeloma | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06082934 | Nov 2023 → Nov 2026 expected | acute lymphoblastic leukemia | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06050512 | Oct 2023 → Oct 2026 | refractory plasma cell neoplasm | Kathleen Dorritie | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05857982 | May 2023 → Jan 2025 | refractory plasma cell neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05647512 | Jan 2023 → Dec 2024 | plasma cell myeloma | LaNova Medicines Limited | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05434689 | Jan 2023 → Aug 2028 expected | plasma cell myeloma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05493618 | Dec 2022 → Nov 2025 | plasma cell myeloma | Hackensack Meridian Health | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04947189 | Nov 2022 → Jul 2026 overdue | triple-negative breast carcinoma | St Vincent's Hospital, Sydney | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05451771 | Oct 2022 → Sep 2027 expected | AL amyloidosis | Columbia University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05432934 | Sep 2022 → Mar 2024 | Crohn disease, colorectal cancer | University of Saskatchewan | Unknown | No outcome recorded |
| Phase 1/2 | NCT05422027 | Jul 2022 → Jun 2025 | plasma cell myeloma | Xia Zhongjun | Unknown | No outcome recorded |
| Phase 1/2 | NCT05136560 | Mar 2022 → Feb 2026 | infectious disease with sepsis | CHA University | Completed | No outcome recorded |
| Phase 1/2 | NCT05060627 | Dec 2021 → Oct 2024 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04973605 | Sep 2021 → Nov 2026 expected | refractory plasma cell neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04766853 | Jul 2021 → Apr 2023 | Meniere disease, drug-induced hearing loss, noise induced hearing loss, sudden hearing loss disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT04551131 | Jul 2021 → Nov 2025 overdue | hemophagocytic syndrome | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04037462 | Jul 2021 → Feb 2022 | non-small cell lung carcinoma | VA Office of Research and Development | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04891744 | Jul 2021 → Dec 2024 | plasma cell myeloma | Li Zheng | Unknown | No outcome recorded |
| Phase 1/2 | NCT04225611 | Mar 2021 → Dec 2027 expected | cystoid macular edema | Massachusetts Eye and Ear Infirmary | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04762745 | Feb 2021 → Feb 2022 | plasma cell myeloma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04300556 | Aug 2020 → Aug 2030 expected | cancer | Eisai Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03952377 | Nov 2019 → Feb 2022 | radiculopathy | SpineThera Australia PTY LTD | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04118296 | Oct → Nov 2019 | acne | Sukma Skin Treatment | Completed | No outcome recorded |
| Phase 1/2 | NCT04126200 | Oct 2019 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04066647 | May → Jul 2019 | — | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03687931 | Aug 2018 → Feb 2019 | eye adnexa disorder | iDrop, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03481556 | Apr 2018 → Feb 2022 | plasma cell myeloma | Oncopeptides AB | Terminated | No outcome recorded |
| Phase 1/2 | NCT03892421 | Apr 2018 → Jan 2021 | non-Hodgkin lymphoma | La Raza Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03492138 | Mar 2018 → Jan 2020 | plasma cell myeloma | Ajai Chari | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02545907 | Sep 2017 → Sep 2019 | amyloidosis | University College, London | Completed | No outcome recorded |
| Phase 1/2 | NCT03220113 | Jul 2017 → Jul 2018 | migraine with aura, migraine without aura | Corona Doctors Medical Clinics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03236792 | Jun 2017 → Sep 2022 | AL amyloidosis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 1/2 | NCT03040011 | Jun 2017 → Apr 2019 | pelvic organ prolapse | Lauren Giugale, MD | Completed | Missed primary |
| Phase 1/2 | NCT02802163 | Jun 2017 → Sep 2020 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03033316 | Jan 2017 → Aug 2020 | plasma cell myeloma | Enceladus Pharmaceuticals BV | Terminated | No outcome recorded |
| Phase 1/2 | NCT02971982 | Oct 2016 → Oct 2018 | — | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02937571 | Oct 2016 → Oct 2024 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02817347 | Jun 2016 → Apr 2017 | discharging ear, otitis media | Yuhan Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02685826 | Apr 2016 → Dec 2017 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02571556 | Nov 2015 → Oct 2016 | cataract 50 with or without glaucoma | Eyegate Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02343042 | Oct 2015 → Apr 2027 expected | plasma cell myeloma | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02542657 | Oct 2015 → Aug 2025 overdue | plasma cell myeloma | Joseph Tuscano | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02485249 | Jul 2015 → Jun 2016 | macular retinal edema | Eyegate Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02389543 | Jul 2015 → Jan 2018 | plasma cell myeloma | Karyopharm Therapeutics Inc | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02348216 | Apr 2015 → Jul 2023 | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Kite, A Gilead Company | Completed | Met primary |
| Phase 1/2 | NCT02006147 | Nov 2014 → Jul 2020 | central retinal vein occlusion with macular edema, occlusion of tributary of retinal vein | Taiwan Liposome Company | Completed | No outcome recorded |
| Phase 1/2 | NCT02309385 | Oct 2014 → Mar 2017 | non-infectious anterior uveitis | Aciont Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT02204241 | Jun 2014 → Jun 2015 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT02057640 | May 2014 → May 2018 | plasma cell myeloma | Jason Valent | Completed | No outcome recorded |
| Phase 1/2 | NCT01946152 | Mar 2014 → Mar 2020 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02004275 | Feb 2014 → Dec 2021 | plasma cell myeloma | Alliance for Clinical Trials in Oncology | Unknown | Met primary |
| Phase 1/2 | NCT01979276 | Nov 2013 → Oct 2016 | plasma cell myeloma | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01857115 | Apr → Nov 2013 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT01754402 | Jan 2013 → Dec 2016 | plasma cell myeloma | Cristina Gasparetto | Unknown | No outcome recorded |
| Phase 1/2 | NCT02145715 | Jan 2013 → Jul 2015 | plasma cell myeloma | Prof Jamie Cavenagh | Unknown | Met primary |
| Phase 1/2 | NCT01794520 | Oct 2012 → Nov 2021 | refractory plasma cell neoplasm | AbbVie | Completed | No outcome recorded |
| Phase 1/2 | NCT01592370 | Aug 2012 → Sep 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01246063 | May 2012 → Dec 2017 | plasma cell myeloma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01522872 | Feb 2012 → Sep 2016 | plasma cell myeloma | Threshold Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT01541332 | Feb 2012 → Dec 2016 | plasma cell myeloma | Oncotherapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT01432600 | Nov 2011 → Aug 2016 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | Met primary |
| Phase 1/2 | NCT01464034 | Nov 2011 → Jul 2020 | plasma cell myeloma | Criterium, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01389427 | Nov 2011 → May 2015 | mantle cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 1/2 | NCT01212952 | Sep 2011 → Aug 2017 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01421186 | Jul 2011 → Aug 2020 | plasma cell myeloma | MorphoSys AG | Completed | No outcome recorded |
| Phase 1/2 | NCT01297764 | Apr 2011 → Jul 2026 overdue | plasma cell myeloma | Hackensack Meridian Health | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01155583 | Jun 2010 → May 2016 | refractory plasma cell neoplasm | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01084252 | May 2010 → Dec 2018 | hematopoietic and lymphoid cell neoplasm | Sanofi | Completed | Met primary |
| Phase 1/2 | NCT01221103 | Apr 2010 → Apr 2012 | mantle cell lymphoma | Southern Europe New Drug Organization | Unknown | No outcome recorded |
| Phase 1/2 | NCT01049945 | Feb 2010 → Nov 2012 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01246557 | Dec 2009 → Apr 2014 | B-cell chronic lymphocytic leukemia | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01029054 | Sep 2009 → Dec 2011 | plasma cell myeloma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00966693 | Aug 2009 → Jul 2018 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00903968 | Jun 2009 → Jun 2016 | plasma cell myeloma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00849251 | Nov 2008 → Dec 2011 | plasma cell myeloma | University of Washington | Terminated | No outcome recorded |
| Phase 1/2 | NCT00750815 | Sep 2008 → Dec 2012 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00708292 | Jul 2008 → Jan 2011 | refractory plasma cell neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00833833 | Jun 2008 → Apr 2011 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 1/2 | NCT00724568 | May 2008 → Apr 2009 | plasma cell myeloma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00981708 | Feb 2008 → Jan 2011 | amyloidosis | University of Athens | Completed | No outcome recorded |
| Phase 1/2 | NCT00793923 | Jan 2008 → Jan 2012 | wet macular degeneration | Subhransu K. Ray, M.D., Ph.D. | Completed | No outcome recorded |
| Phase 1/2 | NCT00531284 | Sep 2007 → Oct 2014 | kidney cancer, non-small cell lung carcinoma, ovarian cancer, plasma cell myeloma +1 | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT00378105 | Sep 2006 → Jul 2009 overdue | plasma cell myeloma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT00401011 | Aug 2006 → Dec 2010 | plasma cell myeloma | AEterna Zentaris | Completed | No outcome recorded |
| Phase 1/2 | NCT00244153 | Jun 2004 → Aug 2007 | rheumatic disorder | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 1/2 | NCT00384553 | Jun 2004 → Jun 2010 | non-Hodgkin lymphoma | University of Magdeburg | Unknown | No outcome recorded |
| Phase 1/2 | NCT00274430 | Jul → Sep 2003 | high altitude pulmonary edema | University of Zurich | Completed | Met primary |
| Phase 1/2 | NCT00308542 | — | diabetic macular edema | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT00308477 | — | macular retinal edema, occlusion of tributary of retinal vein | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
| Phase 2632 trials · 23 met primary · 15 missed | ||||||
| Phase 2 | NCT07605416 | Apr 2027 → Nov 2032 expected | plasma cell leukemia | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT07588698 | Nov 2026 → Aug 2028 expected | diffuse large B-cell lymphoma | Carrie Ho, MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07823192 | Nov 2026 → Jan 2027 expected | — | KRL Hospital, Islamabad | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07803562 | Nov 2026 → Dec 2028 expected | uveal melanoma | University of California, San Diego | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07839195 | Oct 2026 → Jul 2028 expected | arthritis, sacroiliac, arthropathy, chronic pain syndrome, neuritis | Siriraj Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07763210 | Sep 2026 → Mar 2028 expected | diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07811986 | Sep 2026 → Dec 2027 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07698080 | Jul 2026 → Jul 2028 expected | aplastic anemia, leukemia, lymphoma, myelodysplastic syndrome +1 | Hematology department of the 920th hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06818981 | Jul 2026 | obstructive sleep apnea syndrome | Medical University of South Carolina | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06348147 | Jul 2026 → May 2027 | disease related to hematopoietic stem cell transplant, plasma cell myeloma | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Show all 632 trials opens the full record — a long page | ||||||
| Phase 2/347 trials · 3 met primary · 3 missed | ||||||
| Phase 2/3 | NCT07732712 | Jan 2027 → Dec 2028 expected | plasma cell myeloma | The Affiliated People's Hospital of Ningbo University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07095452 | Jan 2026 → Sep 2040 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07853664 | Jan → Dec 2026 expected | — | Thamar University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07059156 | Jun 2025 → Jun 2027 expected | adult acute lymphoblastic leukemia | Shanxi Bethune Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07343128 | Jun → Dec 2025 | fibromyalgia | Sanliurfa Education and Research Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT06212336 | May 2025 → Jun 2027 expected | Lassa fever | Irrua Specialist Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06913374 | May 2025 → May 2026 overdue | primary thrombocytopenia | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06879379 | Mar 2025 → Mar 2028 expected | plasma cell myeloma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07290595 | Jan 2025 → Feb 2026 overdue | hypotensive disorder | Sahiwal medical college sahiwal | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06621329 | Oct 2024 → Jul 2026 overdue | headache disorder, subarachnoid hemorrhage | University of California, Davis | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06496997 | Aug 2024 → Apr 2025 | acute respiratory distress syndrome | Fayoum University | Completed | No outcome recorded |
| Phase 2/3 | NCT07368075 | Jul 2024 → Oct 2025 | hypotensive disorder | Sahiwal medical college sahiwal | Completed | No outcome recorded |
| Phase 2/3 | NCT07590752 | Mar 2024 → Jun 2026 overdue | neuropathy, painful, substance-related disorder | Sahiwal medical college sahiwal | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05998317 | Oct → Nov 2023 | — | Mansoura University | Completed | No outcome recorded |
| Phase 2/3 | NCT05809011 | Apr 2023 → Nov 2025 | heart failure | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Unknown | No outcome recorded |
| Phase 2/3 | NCT05665140 | Feb 2023 → Aug 2027 expected | plasma cell myeloma | University Hopsital Schleswig Holstein Campus Lübeck | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04452565 | Jun 2022 → Dec 2023 | severe acute respiratory syndrome | Biomed Industries, Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT05752305 | Jan 2022 → Jul 2023 | — | University of Granada | Completed | No outcome recorded |
| Phase 2/3 | NCT05145543 | Dec 2021 → Mar 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03692754 | Nov → Dec 2021 | autoimmune thrombocytopenia, thrombocytopenic purpura | Shandong University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05066997 | Oct 2021 → Apr 2026 | diabetic macular edema | Oculis | Completed | No outcome recorded |
| Phase 2/3 | NCT03874936 | Nov 2020 → Dec 2022 | developmental dysplasia of the hip | Odense University Hospital | Completed | Missed primary |
| Phase 2/3 | NCT04563559 | Nov 2020 → Nov 2021 | cataract, glaucoma | Duke University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04513639 | Aug 2020 → Jun 2031 expected | plasma cell myeloma | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02938468 | Sep 2016 → Sep 2021 | — | University of Calgary | Unknown | No outcome recorded |
| Phase 2/3 | NCT03531970 | Aug 2016 → Aug 2017 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02991339 | Jun 2016 → Dec 2017 | hyperbilirubinemia, liver disorder | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02760043 | Apr 2016 → Oct 2018 | osteoarthritis | University Health Network, Toronto | Unknown | Missed primary |
| Phase 2/3 | NCT02751593 | Jan 2016 → Dec 2017 | autoimmune thrombocytopenia, pregnancy disorder | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02491632 | Aug 2015 → Mar 2019 overdue | metastatic malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | Met primary |
| Phase 2/3 | NCT02416388 | Jan 2015 → Jul 2025 overdue | acute myeloid leukemia | University Hospital, Angers | Recruiting | Met primary |
| Phase 2/3 | NCT02111785 | Mar 2014 → Dec 2017 | — | University of Virginia | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT01442428 | Jan 2014 → Mar 2016 | HIV infectious disease, immune reconstitution inflammatory syndrome, tuberculosis | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01790685 | Feb 2013 → Dec 2014 | retinal vein occlusion | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT02552251 | Aug 2012 → Dec 2015 | classic congenital adrenal hyperplasia | University Hospital, Caen | Unknown | No outcome recorded |
| Phase 2/3 | NCT01523314 | Mar → Aug 2012 | diabetic macular edema | King Saud University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02657785 | Sep 2010 → Dec 2028 expected | primary central nervous system lymphoma | Navy General Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02836158 | Sep 2010 → Dec 2025 overdue | primary central nervous system lymphoma | Navy General Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01273727 | Jun 2010 → Apr 2014 | macular retinal edema, preretinal fibrosis | Retina Specialists, PC | Completed | No outcome recorded |
| Phase 2/3 | NCT00861250 | Mar 2009 → Dec 2014 | plasma cell myeloma | Tampere University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00953303 | Jan 2009 → Sep 2011 | heart failure | Hebei Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT00333996 | May 2006 → Mar 2007 | anterior uveitis | Allergan | Terminated | No outcome recorded |
| Phase 2/3 | NCT00592566 | Jul 2003 → Oct 2006 | leptospirosis | Mahidol University | Terminated | No outcome recorded |
| Phase 2/3 | NCT00205751 | Aug 2001 → Oct 2009 | plasma cell myeloma | Austrian Forum Against Cancer | Completed | Met primary |
| Phase 2/3 | NCT00127764 | Jan 2001 → Apr 2005 | pemphigus | University Medical Center Groningen | Completed | Missed primary |
| Phase 2/3 | NCT00038090 | Jun 2000 → May 2005 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00002499 | Jan 1990 → ? | leukemia | Grupo Argentino de Tratamiento de la Leucemia Aguda | Unknown | No outcome recorded |
| Phase 3272 trials · 39 met primary · 28 missed | ||||||
| Phase 3 | NCT07828054 | Dec 2026 → Dec 2030 expected | breast cancer, interstitial lung disease | Mario Negri Institute for Pharmacological Research | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07830108 | Dec 2026 → Dec 2034 expected | rheumatic fever, rheumatic heart disease | Starship Child Health, Te Toka Tumai Auckland | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07861776 | Oct 2026 → Sep 2029 expected | secondary hemophagocytic lymphohistiocytosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07543458 | Oct 2026 → Jul 2030 expected | arbovirus infection, dengue disease, hemorrhagic fever | Oxford University Clinical Research Unit, Vietnam | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07847047 | Oct 2026 → Oct 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07674576 | Sep 2026 → Aug 2028 expected | — | CMC Ambroise Paré | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07576660 | Aug 2026 → Sep 2029 expected | acute respiratory distress syndrome | Southeast University, China | Recruiting | No outcome recorded |
| Phase 3 | NCT07665762 | Aug 2026 → Sep 2028 expected | — | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 3 | NCT07413055 | Mar → Nov 2026 expected | — | Oman Ministry of Health | Recruiting | No outcome recorded |
| Phase 3 | NCT06511765 | Mar → Sep 2026 overdue | lumbar disk disease | Elsan | Recruiting | No outcome recorded |
| Show all 272 trials opens the full record — a long page | ||||||
| Phase 4326 trials · 17 met primary · 23 missed | ||||||
| Phase 4 | NCT07605065 | Nov 2026 → Feb 2027 expected | headache disorder | Pak Emirates Military Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07855341 | Oct 2026 → Aug 2027 expected | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07793760 | Oct 2026 → Oct 2027 expected | preeclampsia | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07795281 | Sep → Dec 2026 expected | — | Gaziantep City Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07699744 | Aug 2026 → Jun 2027 expected | rotator cuff syndrome | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07614802 | Aug 2026 → Aug 2027 expected | — | Duke University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07064993 | Jul 2026 → Feb 2027 expected | — | Arzu Esen Tekeli | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07709884 | Jul 2026 → Dec 2028 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07699315 | Jul → Dec 2026 expected | pulpitis | Watim Medical & Dental College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07357597 | Jun 2026 → Jan 2028 expected | stomatitis | AstraZeneca | Recruiting | No outcome recorded |
| Show all 326 trials opens the full record — a long page | ||||||
| Phase not applicable221 trials · 4 met primary · 8 missed | ||||||
| — | NCT07435493 | Nov 2026 expected | adenoid hypertrophy, obstructive sleep apnea syndrome | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07498998 | Jul → Aug 2026 overdue | carpal tunnel syndrome | Tanta University | Not yet recruiting | No outcome recorded |
| — | NCT07722091 | Jul 2026 → Jan 2027 expected | — | Fujian Medical University Union Hospital | Recruiting | No outcome recorded |
| — | NCT07677215 | Jul 2026 → Sep 2027 expected | osteoarthritis, knee | Poznan University of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT07631910 | Jul → Oct 2026 expected | — | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07672873 | Jun → Dec 2026 expected | pulpitis | Marmara University | Recruiting | No outcome recorded |
| — | NCT07607691 | Jun → Oct 2026 expected | bursitis, chronic pain syndrome, frozen shoulder, rotator cuff syndrome | Ankara City Hospital Bilkent | Not yet recruiting | No outcome recorded |
| — | NCT07584200 | Jun 2026 → Mar 2027 expected | osteoarthritis, hip | Poznan University of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT07550803 | Jun 2026 → Jun 2027 expected | sleep disorder | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07341854 | Jun 2026 → Jun 2027 expected | neuropathy, painful | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Show all 221 trials opens the full record — a long page | ||||||
| Phase not stated6 trials · 1 met primary | ||||||
| — | NCT03969875 | Aug 2018 → Apr 2022 | osteoarthritis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| — | NCT02368301 | — | plasma cell myeloma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| — | NCT04534322 | — | refractory plasma cell neoplasm | Oncopeptides AB | Approved for marketing | No outcome recorded |
| — | NCT02856438 | — | plasma cell myeloma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| — | NCT01250808 | — | plasma cell myeloma | Peking University | Available | No outcome recorded |
| — | NCT00517894 | — | lymphoma | Study Group of Medical Tumour Therapy (AGMT) | No longer available | Met primary |
| Comparator or background therapy1,891 trials | ||||||
| Phase 0 | NCT07485127 Comparator | Feb → Aug 2026 overdue | — | Sohag University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05287035 Comparator | Jul 2023 → Jan 2025 | — | University of Texas at Austin | Unknown | No outcome recorded |
| Phase 0 | NCT05687981 Comparator | Jan → Dec 2023 | — | Tanta University | Unknown | No outcome recorded |
| Phase 0 | NCT05305404 Comparator | Mar 2022 → Jun 2024 | alcohol dependence | Stony Brook University | Completed | No outcome recorded |
| Phase 0 | NCT05142098 Comparator | Jan → Jul 2022 | — | Dow University of Health Sciences | Unknown | No outcome recorded |
| Show all 1,891 trials opens the full record — a long page | ||||||
Press releases naming this drug 139 releases
Evidence & citations 97 cited values
Every value below carries the sentence it was read from. 3,672 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dexamethasone | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗3546“Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone,...” NCT00577096 ↗ “The study aims to evaluate the efficacy and safety of the quadruplet regimen Isatuximab in combination with Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRD) compared to...” NCT07334535 ↗ “This is a randomized, controlled study to assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert when utilized in conjunction...” NCT05665270 ↗ “Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane Ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon...” NCT05331859 ↗ “Recommended rescue medications include tocilizumab for treatment of cytokine release syndrome (CRS); dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related...” NCT07227597 ↗ “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗ “OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D,...” NCT03629210 ↗ “Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of...” NCT05440851 ↗ “The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams,...” NCT04998513 ↗ “The purpose of this study is to find out what the response is and the side effects are with chemotherapy using a combination of drugs called D.T. PACE (Dexamethasone,...” NCT00107614 ↗ |
| Known as | AR-1105 | “PURPOSE: AR-1105 is a novel biodegradable sustained-release dexamethasone implant designed to deliver 6-month durability.” PMID 36542081 ↗ Oct 2022 |
| Known as | AR-1105-CF1 (dexamethasone intravitreal implant) | “AR-1105-CF1 (dexamethasone intravitreal implant)” NCT03739593 ↗ |
| Known as | AR-1105-CF2 (dexamethasone intravitreal implant) | “AR-1105-CF2 (dexamethasone intravitreal implant)” NCT03739593 ↗ |
| Known as | Corodex | “The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)” NCT05924191 ↗ |
| Known as | Decadron | “Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need...” NCT03367988 ↗29“Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each...” NCT00151203 ↗ “Dexamethasone (Decadron) caused minimal damage, while hydrocortisone (Solu-Cortef) and triamcinolone hexacetonide (Aristospan) caused widespread axonal and myelin degeneration.” PMID 7063571 ↗ Mar 1982 “QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle” NCT05480111 ↗ “The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema).” NCT00088166 ↗ “The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block.” NCT04445337 ↗ “A Phase II Study of Dexamethasone (DECADRON®), Thalidomide (THALOMID®), and Lenalidomide (REVLIMID®) for Subjects With Relapsed or Refractory Multiple Myeloma” NCT00538824 ↗ “The names of the study drugs involved in this study are: * Teclistamab * Lenalidomide (also called Revlimid) * Dexamethasone (also called Decadron)” NCT05469893 ↗ “Steroids (such as Decadron or Dexamethasone) are medication used to reduce swelling around the tumour, and thus symptoms improve.” NCT00188864 ↗ “dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine” NCT03641508 ↗ “Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.” NCT01065961 ↗ |
| Known as | Decadron (dexamethasone) | “Decadron (dexamethasone)” NCT00783367 ↗ |
| Known as | Decadron for Dexamethasone | “Decadron for Dexamethasone” NCT01270932 ↗ |
| Known as | Decadron PF | “The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block.” NCT04445337 ↗ |
| Known as | Decort | “The pulp chamber was irrigated with 2 mL of a dexamethasone sodium phosphate solution at a concentration of 4 mg/mL (Decort®, DEVA Holding, Türkiye).” NCT07233577 ↗ |
| Known as | DECTANCYL | “B :dexamethasone (DECTANCYL)” NCT02552251 ↗ |
| Known as | dex | “The non-inferiority of dexamethasone (DEX) on day 1, with or without low-dose DEX on days 2 and 3, combined with oral NEPA (netupitant/palonosetron), compared with the...” PMID 35999527 ↗ Aug 202247“This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of...” NCT05101928 ↗ “The aim of this study is to evaluate the effectiveness of submucosal 8 mg (2 mL) dexamethasone (DEX) on postoperative pain, swelling, chewing efficiency, trismus, healing, and...” PMID 39627624 ↗ Dec 2024 “D (Dexamethasone) group: (n=100) each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS...” NCT03679065 ↗ “PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR...” NCT00002716 ↗ “OBJECTIVE: To compare the efficacy of a single dose of oral dexamethasone (Dex) versus 5 days of twice-daily prednisolone (Pred) in the management of mild to moderate asthma...” PMID 17198210 ↗ Dec 2006 “The combination of dexamethasone (DEX), ondansetron (OND) and droperidol (DRO) is efficacious in preventing postoperative nausea and vomiting in adults, but has not been well...” PMID 28505233 ↗ Jun 2017 “Guidelines recommend the combination of a neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine-3 RA (5-HT3RA), and dexamethasone (DEX) for CINV prophylaxis in...” PMID 28285236 ↗ Mar 2017 “Eligible patients were consecutively enrolled and sequentially assigned in an alternating 1:1 ratio to the dexamethasone (DEX) or control group according to the predefined...” NCT03079453 ↗ “We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA with pomalidomide (POM) and dexamethasone (DEX) in lenalidomide (LEN)/PI-refractory MM.” PMID 34559902 ↗ Oct 2021 “The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patients who have intermediate or high risk smouldering myeloma.” NCT06762769 ↗ |
| Known as | DEX implant | “Dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA)” NCT01581151 ↗ |
| Known as | DEX, dexamethasone | “DEX, dexamethasone” NCT03629210 ↗ |
| Known as | DEX-I | “Dexamethasone Intravitreal Implant (DEX-I, 0.7 mg)” NCT07438119 ↗ |
| Known as | DEXA | “This paper describes the rationale and detailed protocol for a randomised controlled trial evaluating the efficacy of dexamethasone (DEXA) in reducing PES after PAE.” PMID 34725072 ↗ Nov 20212“Patients receive dexamethasone (DEXA) on days 8-28.” NCT00613457 ↗ “Patients receive dexamethasone (DEXA) on days 8-28” NCT00430118 ↗ |
| Known as | DexaEDO | “DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally.” NCT01228149 ↗ |
| Known as | Dexametasone | “Drug: Dexametasone” NCT07068048 ↗ |
| Known as | Dexamethason | “dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection)” NCT04612582 ↗ |
| Known as | Dexamethasone (0.4mg) Insert | “Dexamethasone (0.4mg) Insert” NCT05116345 ↗ |
| Known as | Dexamethasone (Caspian Tamin Pharmaceutical Co, Rasht, Iran) | “Dexamethasone (Caspian Tamin Pharmaceutical Co, Rasht, Iran)” NCT03531970 ↗ |
| Known as | Dexamethasone (D) | “Dexamethasone (D)” NCT01858922 ↗ |
| Known as | Dexamethasone (Decadron) | “Dexamethasone (Decadron®)” NCT02128230 ↗ |
| Known as | Dexamethasone (Decadron, Baycadron) | “Dexamethasone (Decadron, Baycadron)” NCT01297764 ↗ |
| Known as | Dexamethasone (perineural) | “Dexamethasone (perineural)” NCT07584200 ↗ |
| Known as | Dexamethasone - MUP | “Packages and ampoules of dexamethasone and placebo will be identical and contain an equal volume of either a dexamethasone (Dexamethasone - MUP 8 MG / 2 ML (Dexamethasone...” NCT06783634 ↗ |
| Known as | Dexamethasone 21-Phosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04200885 ↗ |
| Known as | dexamethasone acetate | “Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage.” NCT02582177 ↗16“Dexamethasone acetate: Take 12mg orally on the first day of each chemotherapy cycle before chemotherapy, and 3.75mg orally on the second to fourth days twice a day.” NCT07617246 ↗ “Dexamethasone acetate microspheres for extended-release injectable micro-suspension, SX600 at 12.5 mg or 25.0 mg” NCT03952377 ↗ “Dexamethasone/Dexamethasone acetate” NCT06979596 ↗ |
| Known as | Dexamethasone Disodium Phosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02955641 ↗ |
| Known as | Dexamethasone implant | “Patients will receive a Dexamethasone implant and ranibizumab, as needed.” NCT01581151 ↗1“Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally” NCT01284478 ↗ |
| Known as | Dexamethasone implants (Ozurdex, Allergan Inc., Irvine, CA, USA) | “Dexamethasone implants (Ozurdex®, Allergan Inc., Irvine, CA, USA)” NCT04089605 ↗ |
| Known as | Dexamethasone Inj (Dexamethasone disodium phosphate 5㎎) [Daewon Pharm] | “Dexamethasone Inj (Dexamethasone disodium phosphate 5㎎) [Daewon Pharm]” NCT06437054 ↗ |
| Known as | dexamethasone intravitreal implant | “Dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA)” NCT01581151 ↗ |
| Known as | DEXAMETHASONE MYLAN code UCD 9223084 3400892230849 | “DEXAMETHASONE MYLAN code UCD 9223084 3400892230849” NCT02862327 ↗ |
| Known as | Dexamethasone Oral Tablet | “Drug: Dexamethasone Oral Tablet” NCT03199482 ↗ |
| Known as | Dexamethasone phosphate | “Patients received standard dexamethasone (dexamethasone-phosphate 6 mg/d for 10 days [or placebo prior to RECOVERY trial results communication]) or high-dose dexamethasone...” PMID 35788622 ↗ Sep 202220“Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System” NCT00765804 ↗ “20 mg of dexamethasonephosphate (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo” NCT05895838 ↗ “Is usually commercialized as dexamethasone phosphate as solution for injection” NCT04188431 ↗ “Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%” NCT06352541 ↗ “Drug: Dexamethasone phosphate” NCT04816097 ↗ “Drug: Dexamethasone phosphate” NCT05635227 ↗ “Dexamethasone phosphate” NCT04762381 ↗ |
| Known as | Dexamethasone sodium phosphate | “Oncocort Dexamethasone sodium phosphate encapsulated in so-called 'long-circulating' PEGylated liposomes is in development with the prospect of providing enhanced and prolonged...” NCT03033316 ↗40“Patients were treated with a combination of punctal dilation and topical medication in the form of preservative-free steroid eye drops based on dexamethasone sodium phosphate...” NCT06798025 ↗ “Packages and ampoules of dexamethasone and placebo will be identical and contain an equal volume of either a dexamethasone (Dexamethasone - MUP 8 MG / 2 ML (Dexamethasone...” NCT06783634 ↗ “Dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes (EryDex) was developed as an alternative to standard glucocorticoids in an effort to eliminate...” PMID 39917433 ↗ Jan 2025 “Two different commercially available eye drops will be compared: dexamethasone sodium phosphate (Maxidex®, Alcon) in one eye of the patient and artificial tears (Lacrystat®,...” NCT00266838 ↗ “This will be a randomized, double-blind, placebo-controlled clinical research trial testing the efficacy of intravenous dexamethasone sodium phosphate as adjuvant therapy for...” NCT00122278 ↗ “after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle.” NCT03131466 ↗ “EryDex System (EDS) is a combination product used to administer dexamethasone sodium phosphate (DSP) by ex vivo encapsulation in autologous erythrocytes which are re-infused.” NCT02380924 ↗ “Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.” NCT04123561 ↗ “Once the microcatheter is in a good position, 15 mg Dexamethasone Sodium Phosphate and 15 mg of Ketorolac Tromethamine will be infused over 30 minutes.” NCT04353505 ↗ “The pulp chamber was irrigated with 2 mL of a dexamethasone sodium phosphate solution at a concentration of 4 mg/mL (Decort®, DEVA Holding, Türkiye).” NCT07233577 ↗ |
| Known as | dexamethasone sodium phosphate injection | “This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available...” NCT04858776 ↗2“This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available...” NCT04862468 ↗ “0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once” NCT02192827 ↗ |
| Known as | Dexamethasone sodium phosphate injection, 5 mg/1 mL | “Dexamethasone sodium phosphate injection, 5 mg/1 mL” NCT07576660 ↗ |
| Known as | Dexamethasone Sodium Sulfate | “Drug: Dexamethasone Sodium Sulfate” NCT00995501 ↗ |
| Known as | Dexamethasone-21-Sulfobenzoate, Sodium Salt | “Drug: Dexamethasone-21-Sulfobenzoate, Sodium Salt” NCT02953210 ↗ |
| Known as | dexamethasonphosfat | “The dexamethasone kit will contain 20 mg of dexamethasonphosfat (Dexavit®,Vital Pharma Nordic), 4mg/mL, i.e. 5 mL, which corresponds to 16.67 mg of dexamethasone.” NCT05635227 ↗ |
| Known as | Dexaven | “steroid therapy with Dexaven 4 mg / 1 ml - 2 injections at weekly intervals containing single doses of dexamethasone (total dose of 8 mg)” NCT04492774 ↗1“dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously” NCT06609993 ↗ |
| Known as | Dexavit | “The dexamethasone kit will contain 20 mg of dexamethasonphosfat (Dexavit®,Vital Pharma Nordic), 4mg/mL, i.e. 5 mL, which corresponds to 16.67 mg of dexamethasone.” NCT05635227 ↗ |
| Known as | DexSP | “TN-001, the study drug, is a topical eyedrop containing Transforming Growth Factor Beta 3 (TGFB3) and Dexamethasone Sodium Phosphate (DexSP).” NCT07388069 ↗ |
| Known as | DEXTENZA | “DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone...” NCT04521140 ↗19“Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts, when placed within the lower eye lid canaliculus or both the upper and lower canaliculi” NCT04501367 ↗ “Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye).” NCT04479748 ↗ “Dextenza is a sustained-release dexamethasone intracanalicular insert recently approved by the FDA for pain and inflammation post ophthalmic surgery.” NCT04426734 ↗ “Dextenza is a sustained-release dexamethasone intracanalicular insert recently approved by the FDA for pain and inflammation post ophthalmic surgery.” NCT04530864 ↗ “Dextenza is a 0.4mg dexamethasone ophthalmic insert manufactured by Ocular Therapeutix.” NCT05587231 ↗ “Dextenza (dexamethasone ophthalmic insert 0.4mg) 1-3 days prior to cataract surgery” NCT04667507 ↗ “DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use” NCT04728646 ↗ “DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use” NCT05620901 ↗ “Dextenza (dexamethasone) 0.4mg intracanalicular insert delivery system” NCT04687800 ↗ “Ocular Therapeutix Dextenza (Dexamethasone Ophthalmic Insert) 0.4 mg” NCT04549935 ↗ |
| Known as | Dexycu | “A single 0.005-mL anterior chamber injection of DEXYCU (dexamethasoneintraocular suspension) 9%, equivalent to 517mcg dexamethasone.” NCT05191706 ↗2“Intracameral Dexamethasone (Dexycu™)” NCT04781335 ↗ “Dexycu intracameral dexamethasone” NCT04273282 ↗ |
| Known as | disaimisong | “doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)” NCT02577783 ↗ |
| Known as | DSP | “Dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes (EryDex) was developed as an alternative to standard glucocorticoids in an effort to eliminate...” PMID 39917433 ↗ Jan 20254“dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes” NCT06664853 ↗ “dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes” NCT06193200 ↗ |
| Known as | DSP-Visulex | “dexamethasone sodium phosphate Visulex (DSP-Visulex)” NCT02309385 ↗ |
| Known as | DxaM | “The addition of dexamethasone (DxaM) to local anesthetic may significantly prolong the duration of a block.” NCT02190760 ↗ |
| Known as | DXM | “This study compared the efficacy and safety of high-dose dexamethasone (HD-DXM) and conventional prednisone (PDN) on the largest cohort to date as first-line strategies for...” PMID 26480931 ↗ Oct 201517“AIM: To investigate the beneficial and harmful effects of one or two doses of 24 mg intravenous dexamethasone (DXM) as part of a multimodal analgesic regimen (paracetamol,...” PMID 31544230 ↗ Oct 2019 “In this study we want to investigate if combination therapy with rituximab (R) + dexamethasone (DXM) is superior to monotherapy with DXM in patients with newly diagnosed...” NCT00909077 ↗ “Patients in this group will receive a standard root canal treatment but with the extra step of extruding a Dexamethasone (DXM) solution through the root canals to the...” NCT06894069 ↗ “The participants in DXM group will receive a single infusion of a paravertebral space first dose of 21 ml of analgesic containing 0.5 percentage ropivacaine 20 ml and...” NCT05920967 ↗ “The respective benefits of high and low doses of dexamethasone (DXM) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) and acute respiratory failure...” PMID 37634234 ↗ Aug 2023 “Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)” NCT02529774 ↗ “Male and female volunteers received one dose of DXM. Drugs formulations employed were DXM phosphate injectable solution 8 mg/2 mL (Alin, Productos Farmaceuticos, Mexico).” NCT05647408 ↗ “Intravenous (IV) or oral dexamethasone (DXM) reduced 28 d mortality in patients who required supplemental oxygen compared to those who received conventional care alone.” PMID 38290199 ↗ Jan 2024 “Dexamethasone (DXM) instead of PDN is given to all patients with T-ALL without any high-risk criteria as identified by day 8.” NCT01117441 ↗ “The induction therapy is a combination of Blinatumomab(Blina), Vindesine(VDS), Cyclophosphamide(CTX) and Dexamethasone(DXM).” NCT06742515 ↗ |
| Known as | EGP-437 | “Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System” NCT00765804 ↗6“ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS)” NCT01602068 ↗ “Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)” NCT01129856 ↗ “Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)” NCT01505088 ↗ “Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)” NCT02485249 ↗ “Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses.” NCT01059955 ↗ |
| Known as | Epidron | “Dexamethasone sodium phosphate (Epidron®, EIPICO, Cairo, Egypt) is supplied in 4 mg/ml ampule.” NCT03064633 ↗ |
| Known as | epidrone | “the product dexamethasone sodium phosphate intramuscular one hour before the initiation of labor induction in the form of epidrone ampoules which is a dexamethasone product...” NCT03603418 ↗ |
| Known as | Episcleral Dexamethasone | “This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from refractory diabetic macular edema.” NCT04005430 ↗ |
| Known as | EryDex | “Dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes (EryDex) was developed as an alternative to standard glucocorticoids in an effort to eliminate...” PMID 39917433 ↗ Jan 20251“EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)” NCT01925859 ↗ |
| Known as | EryDex System (dexamethasone sodium phosphate encapsulated erythrocytes) | “EryDex System (dexamethasone sodium phosphate encapsulated erythrocytes)” NCT01925859 ↗ |
| Known as | Fortecortin | “The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg...” NCT05120076 ↗2“Dexamethasone (Fortecortin®) will be acquired from ERN, SA. Laboratories (Barcelona, Spain).” NCT04303065 ↗ “Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15” NCT01702233 ↗ |
| Known as | FST-201 | “FST-201 (dexamethasone 0.1%) Otic Suspension” NCT00945802 ↗1“FST-201 (dexamethasone 0.1%) Otic Suspension” NCT00945646 ↗ |
| Known as | HD-DXM | “Therapy of Adults affected by idiopathic thrombocytopenic purpura with 3 cycles pulses of high-dose dexamethasone (HD-DXM): a prospective randomized clinical trial” NCT02914054 ↗5“High-dose dexamethasone (HD-DXM) will be administered orally (40 mg) from day 1-4, followed by Arm 1 or 2 (1:1 randomization).” NCT04812483 ↗ “Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle.” NCT06992128 ↗ “Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle.” NCT06658834 ↗ “Adjunction of dexamethasone (HD DXM)” NCT00777738 ↗ “high-dose dexamethasone [HD-DXM]” NCT00657410 ↗ |
| Known as | hexadecadrol | “methimazole,tapazole;dexamethasone,hexadecadrol” NCT00917241 ↗ |
| Known as | i.v dexmethasone | “Drug: i.v dexmethasone” NCT04778189 ↗ |
| Known as | IDI | “Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)” NCT04527887 ↗ |
| Known as | Inj Dexona | “2 ml in dexamethasone ( 4mg/ml Inj Dexona, Zydus Aliadac, India)” NCT04850885 ↗ |
| Known as | ISV-305 | “The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle” NCT03192150 ↗1“ISV-305 (0.1% Dexamethasone in DuraSite® 2)” NCT03192137 ↗ |
| Known as | IVD | “Will receive intravenous Dexamethasone (IVD)” NCT07861776 ↗ |
| Known as | Maxidex | “Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane Ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon...” NCT05331859 ↗7“A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1%...” NCT01119287 ↗ “Two different commercially available eye drops will be compared: dexamethasone sodium phosphate (Maxidex®, Alcon) in one eye of the patient and artificial tears (Lacrystat®,...” NCT00266838 ↗ “Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye...” NCT04050644 ↗ “dexamethasone ophthalmic suspension (Maxidex®)” NCT03739528 ↗ |
| Known as | Mephamesone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01945554 ↗ |
| Known as | Monofree Dexamethason | “Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye...” NCT04050644 ↗ |
| Known as | Monopex | “Preservative free dexamethasone 0.1% (Monopex) drops for one week” NCT05433428 ↗ |
| Known as | Mylan Dexamethasone | “Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution)” NCT02400047 ↗ |
| Known as | NSC-34521 | “Intrathecal Dexamethasone, IT DM, NSC-34521” NCT00002499 ↗ |
| Known as | OCS-01 | “The goal of this study was to compare topical dexamethasone 1.5% in a novel formulation (OCS-01) once daily and BID versus vehicle for the treatment of inflammation and pain...” PMID 36503736 ↗ Dec 20222“Drug: Dexamethasone ophthalmic suspension (OCS-01)” NCT05066997 ↗ “Dexamethasone ophthalmic suspension (OCS-01)” NCT06172257 ↗ |
| Known as | Oncocort | “Oncocort Dexamethasone sodium phosphate encapsulated in so-called 'long-circulating' PEGylated liposomes is in development with the prospect of providing enhanced and prolonged...” NCT03033316 ↗ |
| Known as | Oradexon | “dexamethasone (Oradexon, Nederland)” NCT00548483 ↗ |
| Known as | OTO-104 | “single intratympanic injection of either 12 mg OTO-104 (otic formulation of dexamethasone in thermosensitive poloxamer) or placebo (1:1) and were observed for 3 months.” PMID 37185596 ↗ Apr 2023 |
| Known as | OTX-DED | “OTX-DED (dexamethasone intracanalicular ophthalmic insert)” NCT05814757 ↗1“OTX-DED (dexamethasone intracanalicular ophthalmic insert)” NCT04747977 ↗ |
| Known as | OTX-DP | “To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular...” NCT01666210 ↗5“The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid...” NCT02445326 ↗ “The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid...” NCT02062905 ↗ “OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects...” NCT02089113 ↗ “OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use” NCT02736175 ↗ “OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use” NCT02468700 ↗ |
| Known as | OZURDEX | “OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D,...” NCT03629210 ↗28“Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by...” NCT01580020 ↗ “The purpose of this study is to determine whether an intravitreal dexamethasone implant (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.” NCT01870440 ↗ “OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.” NCT01903720 ↗ “The main purpose of this study is to evaluate whether or not the dexamethasone pellet (Ozurdex®, Allergan, Irvine, CA) can replace oral corticosteroid” NCT02049476 ↗ “Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator.” NCT01396057 ↗ “intravitreal sustained release dexamethasone implant (Ozurdex®) injected at the conclusion of surgery” NCT01701518 ↗ “Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg)” NCT06536491 ↗ “intravitreal dexamethasone implant (Ozurdex®)” NCT02399657 ↗ “dexamethasone intravitreal implant (Ozurdex)” NCT01410201 ↗ “Ozurdex (dexamethasone) given intravitreally” NCT01787669 ↗ |
| Known as | Ozurdex (dexamethasone intravitreal implant) | “Ozurdex® (dexamethasone intravitreal implant)” NCT01295112 ↗1“OZURDEX® (dexamethasone intravitreal implant)” NCT01478737 ↗ |
| Known as | Phapros | “Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.” NCT06604598 ↗ |
| Known as | ProDex | “Phase I/II Trial of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)” NCT02006147 ↗1“TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)” NCT03093701 ↗ |
| Known as | SMO1 | “SMO1 (Dexamethasone 700μg intravitreal implant)” NCT07708142 ↗ |
| Known as | Soldesam 0.2% | “Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).” NCT00786851 ↗ |
| Known as | Spersadex | “Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery” NCT05331690 ↗ |
| Known as | Spersadex (OmniVision, Novartis Pharma)eye drops. | “Spersadex (OmniVision, Novartis Pharma)eye drops.” NCT00476593 ↗ |
| Known as | Spersadex OmniVision, Novartis Pharma | “Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.” NCT00476593 ↗ |
| Known as | Sterodex | “Dexamethasone (Sterodex)” NCT02825186 ↗ |
| Known as | SX600 | “Dexamethasone acetate microspheres for extended-release injectable micro-suspension, SX600 at 12.5 mg or 25.0 mg” NCT03952377 ↗ |
| Known as | TLC399 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03093701 ↗ |
| Known as | TLC399 (BioSeizer) | “TLC399 (BioSeizer)” NCT02006147 ↗ |
| Known as | Visumetazone | “Visumetazone” NCT01748942 ↗ |
| Action | Activate | “Choline magnesium trisalicylate +/- dexamethasone decreased nuclear NF-kappaB, whereas dexamethasone alone was associated with an increase in nuclear NF-kappaB in AML cells.” PMID 19010875 ↗ Nov 2008 |
| Modality | Small molecule | “dexamethasone-a strong steroid medication” NCT00004990 ↗ |
| Route | Oral | “A fifth medicine (dexamethasone) is given by mouth (PO) on days 1 - 5 of each cycle” NCT00000689 ↗ |
| Target | HDAC2 | “The 3C-like proteinase on SARS-CoV-2 (nsp5) inhibits HDAC2 transport into the nucleus, and so impairs the way in which it mediates inflammation and cytokine responses, so...” NCT04530409 ↗ |